Diurnal Group completes patient enrollment for Chronocort trial

12 February 2018, 14:02

Source - SMW

Diurnal Group said it had successfully completed patient enrollment for its European pivotal clinical trial of Chronocort, a treatment for congenital adrenal hyperplasia in adults.
The Phase III trial was an open label study in which adult patients with CAH, currently treated with a single or combination of generic steroids, were randomised to either receive Chronocort on a twice daily 'toothbrush' regimen or continue on their standard-of-care regimen.
Headline data from the trial was expected in the third quarter and, if positive, could lead to potential market authorisation in Europe in 2020, Duirnal said.
At 2:02pm: (LON:DNL) Diurnal Group Plc share price was +1p at 173.5p

Market Overview

UK 350 Risers and Fallers

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies from this website. If you would like to change your preferences you may do so by following the instructions here.